camrelizumab + SHR9146 + apatinib

**Camrelizumab + SHR9146 + apatinib** is an investigational triple drug combination used in clinical research primarily for treating advanced solid tumors and various cancers. - **Camrelizumab** is a humanized monoclonal antibody that targets the programmed death-1 (PD-1) receptor, thereby blocking PD-1/PD-L1 interactions and activating the immune system to kill cancer cells. - **SHR9146** (sometimes referred to as SHR-1701 or as a code name) is an oral inhibitor of indoleamine 2,3- dioxygenase 1 (IDO1), involved in tryptophan metabolism and immune suppression. - **Apatinib** is a small molecule inhibitor targeting the vascular endothelial growth factor receptor 2 (VEGFR-2), thereby inhibiting angiogenesis (formation of new blood vessels) essential for tumor growth. This combination is developed by Jiangsu Hengrui Pharmaceuticals and is primarily intended for immunotherapy and targeted therapy for cancers such as hepatocellular carcinoma, non-small cell lung cancer, and other advanced solid tumors[1][2][3].

Brand names

camrelizumab (for SHR-1210)Aitan (for apatinib)

Other names

camrelizumab + SHR9146 + apatinib